SEC Form 4 · accession 0001209191-18-002258
GENOMIC HEALTH INC · GHDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James J Vaughn
Officer — Chief Commercial Officer
Period of report
Jan 2, 2018
Accepted (ET)
Jan 4, 2018 · 7:54 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001131324
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 2, 2018 | M | 2,169 | $17.33 | A | 30,481 | D | |
| Common StockF2,F3,F1 | Jan 2, 2018 | S | 2,169 | $34.09 | D | 28,312 | D | |
| Common StockF2,F3,F1 | Jan 2, 2018 | S | 835 | $34.09 | D | 27,477 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F4 | $17.33 | Jan 2, 2018 | M | 2,169 | D | — | Dec 4, 2018 | Common Stock | 0 | 0 | D |
Explanation of responses
- F1Includes an aggregate of 17,374 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
- F2These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on June 8, 2017.
- F3Represents actual sale price.
- F4The option became exercisable as to 25% of the shares on December 4, 2009, and became exercisable as to 1/48th of the shares each full month thereafter.